[1]单国梅,李银翠,孙 卓.替雷利珠单抗联合白蛋白紫杉醇治疗对胃癌患者PD-L1表达、肿瘤相关炎症及远期疗效的影响[J].医学信息,2026,39(10):160-164.[doi:10.3969/j.issn.1006-1959.2026.10.030]
　SHAN Guomei,LI Yincui,SUN Zhuo.Effects of Tislelizumab Combined with Albumin-bound Paclitaxel on PD-L1 Expression, Tumor-related Inflammation, and Long-term Efficacy in Patients with Gastric Cancer[J].Journal of Medical Information,2026,39(10):160-164.[doi:10.3969/j.issn.1006-1959.2026.10.030]
点击复制

替雷利珠单抗联合白蛋白紫杉醇治疗对胃癌患者PD-L1表达、肿瘤相关炎症及远期疗效的影响()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
39卷
期数:
2026年10期
页码:
160-164
栏目:
临床证据信息
出版日期:
2026-05-15

文章信息/Info

Title:
Effects of Tislelizumab Combined with Albumin-bound Paclitaxel on PD-L1 Expression, Tumor-related Inflammation, and Long-term Efficacy in Patients with Gastric Cancer
文章编号:
1006-1959（2026）10-0160-05
作者:
单国梅; 李银翠; 孙 卓
成武县人民医院肿瘤内科，山东 成武 274200
Author(s):
SHAN Guomei;  LI Yincui;  SUN Zhuo
Department of Oncology, Chengwu County People′s Hospital, Chengwu 274200, Shandong, China
关键词:
替雷利珠单抗; 白蛋白紫杉醇; 胃癌; PD-L1; 预后
Keywords:
Tislelizumab;  Albumin-bound paclitaxel;  Gastric cancer;  PD-L1;  Prognostic
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2026.10.030
文献标志码:
A
摘要:
目的 研究替雷利珠单抗联合白蛋白紫杉醇治疗胃癌对程序性死亡配体-1（PD-L1）表达、肿瘤相关炎症及远期疗效的影响。方法 选取2023年2月-2024年2月我院诊治70例胃癌患者为研究对象，采用随机数字表法分为对照组和研究组，各组35例。对照组采用白蛋白紫杉醇+卡培他滨片治疗，研究组在对照组基础上给予替雷利珠单抗治疗，对比两组近期疗效、PD-L1和程序性死亡受体-1（PD-1） mRNA相对表达量、肿瘤相关炎症因子水平[白细胞介素-8（IL-8）、肿瘤坏死因子-α（TNF-α）]、预后效果、不良反应发生率。结果 研究组疾病控制率（77.14%）高于对照组（57.14%）（P＜0.05）；两组治疗后PD-L1 mRNA、PD-1 mRNA相对表达量均低于治疗前，且研究组低于对照组（P＜0.05）；两组治疗后IL-8、TNF-α水平均低于治疗前，且研究组低于对照组（P＜0.05）；研究组无进展生存期、总生存期均大于对照组（P＜0.05）；研究组不良反应发生率（17.14%）与对照组（20.00%）无差异（P＞0.05）。结论 替雷利珠单抗联合白蛋白紫杉醇治疗胃癌可降低PD-L1表达，抑制肿瘤相关炎症反应，提高疾病控制率，延长患者无进展和总生存期，且不增加临床不良反应发生率，值得临床加以应用。
Abstract:
Objective To investigate the effects of tislelizumab combined with albumin-bound paclitaxel on programmed death-ligand 1 (PD-L1) expression, tumor-related inflammation, and long-term efficacy in gastric cancer treatment. Methods A total of 70 patients with gastric cancer admitted to our hospital from February 2023 to February 2024 were enrolled as study subjects and randomly divided into a control group and a study group using a random number table method, with 35 patients in each group. Patients in the control group received treatment with albumin-bound paclitaxel+capecitabine tablets, whereas those in the study group were treated with tislelizumab in addition to the regimen administered to the control group. The two groups were compared in terms of short-term efficacy, relative mRNA expression levels of programmed death-ligand 1 (PD-L1) and programmed cell death protein-1 (PD-1), tumor-related inflammatory cytokines levels [interleukin-8 (IL-8) and tumor necrosis factor-alpha (TNF-α)], prognostic outcomes, and incidence of adverse reactions. Results The disease control rate of the study group (77.14%) was higher than that of the control group (57.14%) (P<0.05). After treatment, the relative expression levels of PD-L1 mRNA and PD-1 mRNA in the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P<0.05). After treatment, the levels of IL-8 and TNF-α in the two groups were lower than those before treatment, and those in the study group were lower than those in the control group (P<0.05). The progression-free survival and overall survival of the study group were higher than those of the control group (P<0.05). The incidence of adverse reactions in the study group (17.14%) was not significantly different from that in the control group (20.00%) (P>0.05). Conclusion Tislelizumab combined with albumin-bound paclitaxel in the treatment of gastric cancer can reduce the expression of PD-L1, inhibit tumor-related inflammatory response, improve disease control rate, prolong progression-free survival and overall survival of patients, and do not increase the incidence of clinical adverse reactions, which is worthy of clinical application.

参考文献/References:

[1]孟春芹,刘先勇,吴皞,等．健脾化瘀方治疗结直肠癌脾虚瘀毒型的疗效及对肠道菌群和免疫功能的影响[J].河北中医,2023,45(6):944-947,951.[2]李琪儿,朱春霞,胡桂梅.胃蛋白酶原和胃泌素-17在胃部疾病中的诊断价值[J].现代实用医学,2022,34(7):862-864.[3]付海琴,南阳光,李春燕,等.白蛋白紫杉醇与卡铂联合替雷利珠单抗治疗晚期非小细胞肺癌的效果[J].西北药学杂志,2023,38(4):164-168.[4]刘爽,刘倩,庞茜茜,等.替雷利珠单抗联合化疗治疗Ⅲb~Ⅳ期非小细胞肺癌的效果[J].实用医院临床杂志,2024,21(3):112-116.[5]陆舜,余新民,胡艳萍,等.替雷利珠单抗联合化疗一线治疗局部晚期或转移性非鳞状非小细胞肺癌的肿瘤缓解特征[J].中华肿瘤杂志,2023,45(4):358-367.[6]Hauser SL,Kappos L,Mnotalban X,et al.Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis[J].Neurology,2021,97(16):e1546-e1559.[7]郑雷振,刘现立.不同辅助化疗方案联合手术治疗进展期胃癌的疗效比较[J].实用临床医药杂志,2021,25(5):26-29.[8]国抗癌协会胃癌专业委员会.胃癌诊治难点中国专家共识(2020版)[J].2020,40(8):869-904.[9]鲍予頔,张辉,董雷,等.局部进展期胃癌术后进行奥沙利铂联合替吉奥辅助化疗的安全性和有效性[J].中华胃肠外科杂志,2021,24(2):145-152.[10]益平,何杨,盛莉莉.XELOX与SOX方案在胃癌辅助治疗中的临床观察[J].皖南医学院学报,2021,40(3):232-236.[11]Xia JY,Aadam AA.Advances in screening and detection of gastric cancer[J].J Surg Oncol,2022,125(7):1104-1109.[12]胡欢.FLOT与FOLFOX方案对进展期胃癌术后化疗的差异性评价: 一项倾向性匹配分析[D].兰州:兰州大学,2020.[13]Zhan QQ,Liu QY,Yang X,et al.Effects of silencing neuropilin-2 on proliferation,migration,and invasion of colorectal cancer HT-29 [J].Bioengineered,2022,13(4):11042-11049.[14]延群,莫海云.DOF方案与XELOX方案一线治疗进展期胃癌疗效对比[J].中华肿瘤防治杂志,2021,28(10):782-787.[15]叶春,祁兴顺,李谦谦,等.XELOX联合曲妥珠单抗在HER2阳性老年晚期胃癌转化治疗中的疗效观察[J].中国普外基础与临床杂志,2022,29(12):1623-1627.[16]朱益平,何杨,盛莉莉.XELOX与SOX方案在胃癌辅助治疗中的临床观察[J].皖南医院学报,2021,40(3):232-236.[17]文博,赵赟博.PD-1抑制剂联合化疗治疗晚期胃癌临床观察[J].山东医药,2021,61(16):80-84.[18]黄晓鹏.替雷利珠单抗联合改良DCF方案治疗晚期胃癌临床研究[J].实用中西医结合临床,2023,23(15):41-43.[19]朱亚宁,王鹏翀,史先鹏,等.替雷利珠单抗用于晚期胃癌一线治疗的拓展性应用评价[J].肿瘤药学,2023,13(5):621-630.[20]殷国庆,王忠,周峰,等.替吉奥与阿帕替尼单药二线治疗晚期胃癌伴肝转移的效果对比[J].广西医学,2020,42(4):425-428.[21]雒雷鸣,赵伟峰,张永喜.替吉奥联合伊立替康与雷替曲塞联合伊立替康治疗晚期胃癌的疗效观察[J].癌症进展,2020,18(23):2431-2434.[22]万里,王鹏,王晖,等.白蛋白结合型紫杉醇联合奥沙利铂一线治疗晚期胃癌的临床观察[J].中国药房,2022,33(13):1630-1634.[23]徐泽宇,汪海岩,田园.卡瑞利珠单抗联合白蛋白紫杉醇二线治疗晚期胃癌的疗效及安全性[J].现代肿瘤医学,2023,31(1):130-134.[24]罗详冲,王周清,李琼艳,等.PD-1抑制剂替雷利珠单抗治疗晚期恶性肿瘤的药理作用与临床评价[J].协和医学杂志,2022,13(4):679-686.

相似文献/References:

[1]程家松.替雷利珠单抗联合DP化疗方案治疗晚期肺癌的临床效果及对免疫功能的影响[J].医学信息,2023,36(22):136.[doi:10.3969/j.issn.1006-1959.2023.22.031]
　CHENG Jia-song.Clinical Effect of Tirelizumab Combined with DP Chemotherapy in the Treatment of Advanced Lung Cancer and its Effect on Immune Function[J].Journal of Medical Information,2023,36(10):136.[doi:10.3969/j.issn.1006-1959.2023.22.031]
[2]韩 寒,陈雨晨,刘 洋,等.替雷利珠单抗治疗晚期非小细胞肺癌患者的真实世界研究[J].医学信息,2025,38(08):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]
　HAN Han,CHEN Yuchen,LIU Yang,et al.A Real-world Study of Tislelizumab in the Treatment of Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2025,38(10):80.[doi:10.3969/j.issn.1006-1959.2025.08.016]
[3]熊琼琼.替雷利珠单抗联合铂类治疗中晚期非小细胞肺癌的临床效果[J].医学信息,2025,38(10):130.[doi:10.3969/j.issn.1006-1959.2025.10.025]
　XIONG Qiongqiong.Clinical Effect of Tirelizumab Combined with Platinum in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2025,38(10):130.[doi:10.3969/j.issn.1006-1959.2025.10.025]

更新日期/Last Update: 1900-01-01